Division of Biostatistics & Bioinformatics In the Department of Family & Preventive Medicine
Jump to Navigation

Steven D. Edland

Professor

9500 Gilman Dr #0948
San Diego, CA 92093-0948
858 246-1250
sedland at ucsd dot edu

Dr. Edland’s primary research interest is the epidemiology, treatment, and prevention of chronic disease.  Prior to joining UCSD, Dr. Edland provided statistical support to a number of nationally recognized epidemiologic investigations of Alzheimer’s disease, including the Consortium the Establish a Registry of Alzheimer’s Disease, the first nationwide longitudinal cohort study of Alzheimer’s disease, the Mayo Clinic medical records-based Olmsted County Rochester Epidemiology Project, the “Kame study” of the prevalence, incidence, and risk factors for dementia and Alzheimer’s disease in the Japanese-American residents of King County, WA, and other NIA program project Alzheimer’s disease model patient registries.  Dr. Edland’s expertise in longitudinal analysis is now brought to bear in support of cohort studies and clinical trials administered by the UCSD Department of Neuroscience, where he has a joint appointment.

Dr. Edland enjoys the collaborative research process and bridging the gap between mathematical statistics and research application, with substantial experience supporting both clinical and bench research, including 21 years of continuous involvement in Alzheimer’s Disease Research Centers (ADRCs), as founding director of the Mayo Clinic ADRC Biostatistics Core, and currently as director of the UCSD ADRC Biostatistics Core.  Dr. Edland’s collaborations often evolve into ancillary publication of context-specific statistical methods.

Dr. Edland’s current active independent research is on the improved design, implementation, and analysis of clinical trials of chronic progressive disease such as Alzheimer’s disease.  Dr. Edland is a standing member of the NIH Special Emphasis Panel Alzheimer’s Disease Pilot Clinical Trials (PAR 11-100), serves on Data Safety Monitoring Boards for several multinational clinical trials, and is PI of an NIA grant to advance novel designs and analysis plans for performance of Alzheimer’s disease treatment trials.

Selected Publications:

  • Morris, JC; Edland, S; et al. (1993) The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology 43(12):2457-2465.
  • Hearn, MG; Edland, SD; et al. (1994) Trypsin inhibitor activities of fibroblasts increase with age of donor and are unaltered in familial Alzheimer's disease. Experimental Gerontology 29(6):611-662.
  • Edland, SD. (1996) Bias in slope estimates for the linear errors in variables model by the variance ratio method. Biometrics 52(1):243-248.
  • Edland, SD; et al.  (1999) Estimation and sample design in prevalence surveys of dementia. Journal of Clinical Epidemiology 52(5):399-403.
  • Edland, SD. (2000) How and when to test the relationship between level and longitudinal rate of change. Statistics in Medicine 19(11):1441-1152.
  • Edland, SD; et al. (2002) Dementia and Alzheimer’s disease incidence rates do not vary by sex in Rochester, Minn.  Archives of Neurology 59(10):1589-1593.
  • Edland, SD; et al. (2002) Mitochondrial genetic variants and Alzheimer's disease: a case-control study of the T4336C and G5460A variants. Alzheimer Disease and Associated Disorders 16(1):1-7.
  • Edland, SD; et al. (2003) Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: evidence of effect modification by apolipoprotein E. Neuroscience Letters 345:21-24.
  • Edland, SD; et al. (2004) Genetic association studies in Alzheimer's disease research: challenges and opportunities. Statistics in Medicine 23(2):169-178.
  • Knopman, DS; Edland, SD; et al. (2007) Incident dementia in women is preceded by weight loss by at least a decade. Neurology 69(8):739-746.
  • Lu, PH; Edland, SD; et al. (2009) Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology 72(24): 2115-2121.
  • Vozdolska, R; Sano, M; Aisen, P; Edland, SD. (2009) The net effect of alternative allocation ratios on recruitment time and trial cost. Clinical Trials 6(2): 126-132.
  • Edland, SD; et al. (2010) NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia. Alzheimer’s Disease & Associated Disorders 24(2): 159-164.
  • McEvoy, LK; Edland, SD; et al. (2010) Neuroimaging Enrichment strategy for secondary prevention trials in Alzheimer disease. Alzheimer Disease & Associated Disorders 24(3): 269-277.
  • Ard, MC and Edland, SD (2011) Power calculations for clinical trials in Alzheimer's disease. Journal of Alzheimer’s Disease. 21:369-377.
  • Smith, JR; Edland, SD; et al. (2011) Increasing hookah use in California. American Journal of Public Health. 101(10):1876-1879.
  • Brody, BL; Field, LC; Roch-Levecq, AC; Moutier CY; Edland, SD; Brown, SI. (In Press) Treatment of depression associated with age-related macular degeneration in a double-blind randomized controlled study. Annals of Clinical Psychiatry.
  • Ard, MC; Galasko, DR; Edland, SD. (In Press) Improved Statistical Power of Alzheimer Clinical Trials by Item Response Theory: Proof of Concept by Application to the Activities of Daily Living Scale. Alzheimer's Disease and Associated Disorders.
Back to Top

External Resources: